test

Dan-Arin Silasi MD

Associate Professor of Obstetrics, Gynecology, and Reproductive Sciences; Director, 'Discovery to Cure' International Fellowship Program in Gynecologic Oncology; Director, Obesity Robotic Pelvic Surgery Program

Clinical Interests

Gynecologic cancers (ovarian, uterine, cervical, vulvar, and vaginal cancers); Gestational trophoblastic neoplasia; Complicated laparoscopic surgery; Robotic surgery; Single-port laparoscopic surgery; Advanced and complicated pelvic surgery; Chemotherapy for gynecologic cancers


Board Certifications

2010
Obstetrics & Gynecology, Board Certified
2012
Gynecologic Oncology, Board Certified

Patient Care Locations

dan-arin_silasifaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
A PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY AS PRIMARY TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER COMPARED TO CHEMORADIATION ALONE: THE OUTBACK TRIAL (ANZGOG 0902/GOG-0274/RTOG 1174)
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
An open label Phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose of the anti-mesothelin antibody drug conjugate BAY 94-9343 in subjects with advanced solid tumors
Other Female GenitalA Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Detection of Sentinel Lymph Nodes in Patients with Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes with Fluorescence Imaging

More Clinical Trials...

Edit Profile